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Antibodies against acetylcholine receptors (AChRs)
cause pathogenicity in myasthenia gravis (MG) pa-
tients through complement pathway-mediated de-
struction of postsynaptic membranes at neuromuscu-
lar junctions (NMJs). However, antibodies against
muscle-specific kinase (MuSK), which constitute a
major subclass of antibodies found in MG patients, do
not activate the complement pathway. To investigate
the pathophysiology of MuSK-MG and establish an
experimental autoimmune MG (EAMG) model, we in-
jected MuSK protein into mice deficient in comple-
ment component five (C5). MuSK-injected mice si-
multaneously developed severe muscle weakness,
accompanied by an electromyographic pattern such
as is typically observed in MG patients. In addition,
we observed morphological and functional defects in
the NMJs of EAMG mice, demonstrating that comple-
ment activation is not necessary for the onset of
MuSK-MG. Furthermore, MuSK-injected mice exhibited
acetylcholinesterase (AChE) inhibitor-evoked cholin-
798ergic hypersensitivity, as is observed in MuSK-MG
patients, and a decrease in both AChE and the AChE-
anchoring protein collagen Q at postsynaptic mem-
branes. These findings suggest that MuSK is indis-
pensable for the maintenance of NMJ structure and
function, and that disruption of MuSK activity by au-
toantibodies causes MG. This mouse model of EAMG
could be used to develop appropriate medications for
the treatment of MuSK-MG in humans. (Am J Pathol
2012, 180:798–810; DOI: 10.1016/j.ajpath.2011.10.031)
Myasthenia gravis (MG), the most common disorder of
neuromuscular synapses, is caused by autoantibodies
against postsynaptic membranes at neuromuscular junc-
tions (NMJs).1,2 The characteristic clinical features of this
autoimmune disease include ptosis, fatigue, and muscu-
lar weakness. In 2001, autoantibodies against muscle-
specific kinase (MuSK) were found in 70% of patients
with generalized MG who lacked antibodies to acetylcho-
line receptors (AChRs).3 MuSK, a receptor tyrosine ki-
nase, is concentrated at NMJs from the earliest stages of
synaptogenesis and is required for the formation of NMJs
during development.4 Recent studies demonstrated that
MuSK is activated by dimerization with low-density lipo-
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ing to LRP4.5,6
We previously developed a model of experimental au-
toimmune myasthenia gravis (EAMG) caused by MuSK
antibodies (MuSK Abs) by active immunization of rabbits
with recombinant soluble MuSK protein.7 In addition,
passive transfer of human MuSK Abs from MG patients
into mice was shown to cause MG.8 These studies not
only demonstrate the pathogenicity of MuSK Abs in the
onset of MG, but also suggest that MuSK is required for
the maintenance of mature NMJs.
Although previous studies have suggested that the
disruption of NMJ maintenance by MuSK Abs might
cause MG, several questions remain regarding the pa-
thology of MuSK-MG. First, MuSK Abs in MG patients are
mainly composed of the IgG4 subclass.9,10 IgG4 anti-
bodies do not activate the classical complement path-
way, and thus cannot act through the same mechanism
observed for AChR antibodies in MG.2 Additionally, sev-
eral studies have shown that small amounts of addi-
tional complement-fixing subclasses of MuSK and
AChR Abs are also detectable in MuSK-MG pa-
tients,9–11 casting doubt on the pathogenicity of MuSK
Abs. Therefore, it is essential to determine whether
MuSK Abs cause MG without complement activation.
Second, a number of clinical studies have shown that
MuSK-MG constitutes a distinct subclass of MG. For ex-
ample, patients with MuSK-MG are more prone to severe
muscle weakness with respiratory crises and eventual
atrophy than those with AChR-MG,12,13 and thus require
emergent and aggressive therapies. In addition, although
acetylcholinesterase (AChE) inhibitors are often used ef-
fectively as symptomatic treatment for AChR-MG,1,2
MuSK-MG patients frequently either are unresponsive to
this treatment or develop cholinergic crises character-
ized by increasing muscle weakness.14 A thorough un-
derstanding of the unique pathophysiology of MuSK-MG
is crucial for the development and assessment of appro-
priate medications in the future.
To resolve this critical issue, we generated a new an-
imal model in which 100% of mice synchronously de-
velop EAMG after immunization with MuSK protein. This
model not only reveals the pathogenic mechanisms in-
volved in MuSK-MG, but also clarifies the role of MuSK at
mature NMJs.
Materials and Methods
Preparation of Recombinant MuSK Protein
The fusion protein expression construct, consisting of the
rat MuSK ectodomain and a 3= myc/His-tag sequence,
was generated as described previously.7 293-F cells
were transfected with FreeStyle MAX reagent (Invitrogen)
according to the manufacturer’s instructions. Secreted
recombinant MuSK protein was purified using Ni-Sephar-
ose (GE Healthcare, Piscataway, NJ), pooled, and con-
centrated. The purity of the recombinant protein was de-
termined by SDS-PAGE with Coomassie blue staining,
and the concentration was determined using a Quant-iTassay kit (Invitrogen) with bovine serum albumin as a
standard.
Immunization of Mice
All animal procedures used were approved by the Animal
Care and Use Committee of Tokyo Metropolitan Geriatric
Hospital and Institute of Gerontology. A/WySnJ and C3-
deficient mice were obtained from the Jackson Laboratory
(Bar Harbor, ME). A/J, B10.A-H2a, BALB/c, and C57BL/6
mice were obtained from Japan SLC (Hamamatsu, Ja-
pan). DBA/2 and FVB/N mice were obtained from CLEA
Japan (Fuji, Japan). All mice were used after 8 weeks of
age. On day 0, adult female mice were anesthetized with
tribromoethanol and injected subcutaneously in the hind
footpads with 20 g MuSK emulsified with complete
Freund’s adjuvant. All mice were boosted with 20 g
MuSK emulsified with incomplete Freund’s adjuvant on
day 14. All C57BL/6J and C3-deficient mice received a
third injection of the same dose emulsified with incom-
plete adjuvant on day 28. Control mice were injected with
equal volumes of PBS or equal doses of ovalbumin (OVA)
emulsified with adjuvant in the same manner and on the
same schedule. For comparison with MuSK-injected
mice, A/WySnJ mice were injected with 20 g AChR
protein, which was purified from Torpedo californica as
described previously15 and emulsified with adjuvant on
days 0, 14, and 42. When antigen-immunized mice ex-
hibited a prominent cervical hump and gait disturbance,
they were analyzed for EAMG.
Measurement of Muscle Strength
Forelimb muscle strength was determined by using an
MK-380M grip strength meter (Muromachi Kikai, Tokyo,
Japan). Mice were allowed to grip the cage lid while
being held by the tail, with hindlimbs suspended, and
were pulled horizontally until the grip was released.
Seven measurements were performed per mouse. The
highest and lowest values were discarded, and the aver-
age of the five remaining measurements was used for
statistical evaluation.
Measurements of Titer and Subclasses of
MuSK Antibodies
Wells of ELISA plates were coated with purified rat MuSK
(150 ng/well) diluted in Tris-buffered saline. After a wash-
ing with 0.1% Tween-20/Tris-buffered saline, plates were
blocked with 4% BlockAce (Dainippon Pharmaceutical,
Osaka, Japan), then incubated for 3 hours at 37°C with
diluted sera (1:1000 in Tris-buffered saline) from MuSK-
immunized and preimmune mice. The plates were
washed and then incubated for 1 hour at 37°C with HRP-
conjugated antibodies against anti-mouse IgG (1:3000 in
0.1% Tween-20/Tris-buffered saline; GE Healthcare), fol-
lowed by another washing and reaction with a 3,3=,5,5=-
tetramethylbenzidine liquid substrate system (Sigma-Al-
drich, St. Louis, MO). The colorimetric reaction was
stopped by 2 mol/L HCl (2N HCl), and the values of
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antibodies. Subclasses of MuSK antibodies were deter-
mined using a Mouse Typer sub-isotyping kit (Bio-Rad
Laboratories, Hercules, CA) according to the manufac-
turer’s instructions. Only the measurement of IgE was
performed by using antibody (Nordic Immunological
Laboratories, Eindhoven, The Netherlands) not in the kit.
In isotyping analysis, sera from MuSK-immunized mice
were diluted 1:3000.
Electromyography
Changes in compound muscle action potential (CMAP)
were studied using a PowerLab 4/26 data acquisition
system (ADInstruments, Colorado Springs, CO). Mice
were anesthetized with tribromoethanol and maintained
at 37°C on a thermoregulation device. Paired stimulating
electrodes separated by 2 to 3 mm were inserted intra-
muscularly near the sciatic notch for supramaximal stim-
ulation at 3 Hz. Recording electrodes were inserted in the
medial compartment of the gastrocnemius muscle and
near the insertion of the Achilles tendon. To isolate stim-
ulus artifacts, a ground electrode was placed between
the stimulus and recording electrodes. Decrement was
calculated as percent amplitude change between the
first and least CMAPs evoked by a train of 10 impulses. If
the amplitude of the first CMAP was the least within the
measurement, the decrement was designated as 0%. In
drug treatment experiments, neostigmine bromide (37.5
g/kg; Sigma-Aldrich) was given by intraperitoneal injec-
tion. A typical mouse weighing 20 g received 100 L of
freshly prepared solution containing 7.5 g/mL of
neostigmine bromide in PBS. After 20 minutes, the effect
of drug treatment was evaluated via electromyography
(EMG).
In Vitro Electrophysiology
Left phrenic nerve and hemi-diaphragm muscle prepara-
tions were made after tribromoethanol anesthetization.
The muscle specimen was placed in a 1.0-mL chamber
filled with Tyrode’s solution, which was constantly oxy-
genized by a gas mixture of 95% O2/5% CO2 released
close to the fluid surface. Membrane potentials and min-
iature endplate potentials (MEPPs) were recorded at
room temperature (18°C to 22°C) using a glass micro-
electrode filled with 3 mol/L KCl via a PowerLab 4/26 data
acquisition system. To measure evoked endplate poten-
tials (EPPs), -conotoxin GIIIB (Peptide Institute, Osaka,
Japan) was added to the chamber (1 mol/L final con-
centration) to suppress muscle contraction, and the
phrenic nerve was stimulated by silver electrodes with
supramaximal voltage at 0.7 Hz. Amplitudes of EPPs and
MEPPs were standardized to a membrane potential of
75 mV. Quantal content was calculated by applying the
values of mean MEPP amplitude, mean EPP amplitude,
and membrane potential in the same muscle fiber to a
formula reported previously.16,17 To analyze rate of EPP
decay, an exponential function was fitted to the falling
phase portion from 80% to 20% of EPP peak value, and
the decay time constant () was calculated using thePeak Parameter program in the LabChart software
package (version 7.1.2; ADInstruments). The MEPP
frequency was calculated from a 1 minute recording
in each NMJ. To exclude the effects of -conotoxin
treatment and nerve stimulation on spontaneous neu-
rotransmission, frequency measurements were per-
formed separately from those of quantal content. Data
for 10 NMJs were obtained from each normal or
MuSK-immunized mouse.
Whole-Mount Staining of NMJs
For quantification of nerve terminals and AChR and AChE
staining areas, whole-mount staining of soleus muscles
was performed. Soleus muscles were removed and fixed
in 1% paraformaldehyde/PBS for 10 minutes at room
temperature, rinsed in PBS, and incubated with 0.1 mol/L
glycine/PBS. After filleting muscles into several sheets of
fibers using microdissection scissors, muscle slices were
incubated with either rhodamine or Alexa Fluor 647-con-
jugated -bungarotoxin (BTx, 40 nmol/L in PBS; Invitro-
gen) to label AChRs for 1 hour at room temperature.
Muscles were then rinsed in PBS, permeabilized in meth-
anol at 20°C, washed again in PBS for 30 minutes, and
blocked for 1 hour in 2% bovine serum albumin/0.3%
TritonX-100/PBS. Slices were then incubated overnight at
4°C in a cocktail of primary antibodies diluted in blocking
solution. Axons and nerve terminals were labeled with
rabbit polyclonal antibodies against neurofilament (1:
400; Millipore-Chemicon International, Temecula, CA)
and synaptophysin (1:100; Invitrogen).
For quantification of nerve terminals, muscles were
incubated only with anti-synaptophysin. Rabbit poly-
clonal antibody against AChE (1:1000) was generated by
Dr. Terrone L. Rosenberry (Mayo Clinic College of Med-
icine). Antiserum against collagen Q (ColQ, 1:2000) was
prepared by injecting Wistar rats with a synthetic peptide
corresponding to residues 35 to 51 of the ColQ deduced
primary sequence coupled to keyhole limpet hemocya-
nin. After incubation with primary antibodies, muscles
were rinsed three times (20 minutes each) in PBS and
incubated overnight at 4°C with either Alexa Fluor 488- or
Alexa Fluor 555-conjugated secondary antibodies (1
g/mL in blocking solution; Invitrogen) corresponding to
the hosts of the primary antibodies. After incubation with
secondary antibodies, muscles were rinsed three times
(20 minutes each) in PBS and flat-mounted in a SlowFade
antifade kit (Invitrogen) for confocal microscopic analy-
sis. For quantification of AChR staining intensity, dia-
phragms were dissected and fixed in 1% paraformalde-
hyde/PBS for 1 hour at room temperature, rinsed in PBS,
and incubated with 0.1 mol/L glycine/PBS. Some pieces
of left hemi-diaphragm were incubated overnight at 4°C
with Alexa Fluor 488-BTx (40 nmol/L in PBS; Invitrogen).
Muscles were then rinsed three times (20 minutes each)
in PBS and flat-mounted in the same way as soleus mus-
cles. Confocal images were acquired with a Leica TCS
SP5 confocal laser scanning unit, using a 63 glycerin
objective on a Leica DMI6000 microscope (Leica Micro-
systems, Wetzlar, Germany), and images of 30 NMJs
were acquired from each control or MuSK-immunized
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tophysin, AChR and AChE staining areas were quantified
on a maximum projection of confocal images with ImageJ
software (version 1.42q; NIH, Bethesda, MD). The ImageJ
Analyze Particle program was used to quantify the areas of
each staining experiment.
Electron Microscopy
After tribromoethanol anesthetization, tibialis anterior
muscles were exposed and fixed in situ with 4% glutar-
aldehyde/0.1 mol/L phosphate buffer at pH 7.3 for 5
minutes. Muscles were then dissected, cut into small
strips, postfixed with the same solution for 2 hours at
room temperature, rinsed several times in distilled water,
and further postfixed with 1% unbuffered osmium tetrox-
ide for 30 minutes. For SEM observation, muscles were
treated with a HCl-hydrolysis procedure to remove intra-
muscular connective tissues as described previously.18
After a drying via the critical point method and then a
sputter coating with platinum, specimens were examined
in a Hitachi S-800 SEM (Hitachi High-Technologies, To-
kyo, Japan). For TEM observation, diaphragms were
fixed in situ by injecting the fixative intrathoracically and
intraperitoneally until these cavities were filled. Small
pieces of fixed muscle were block-stained with 3% aque-
ous uranyl acetate for 2 hours and embedded in Epon
812 resin (Nissin EM, Tokyo, Japan) after dehydration
through an ethanol series. Ultrathin sections were cut with
an Ultracut E ultramicrotome (Reichert-Jung, Austria),
doubly stained with uranyl acetate and lead citrate, and
then examined with a Hitachi HU-12A transmission mi-
croscope (Hitachi High-Technologies). For morphometric
analysis, TEM images were scanned and the density of
junctional folds was determined by the number of folds
divided by the length of the presynaptic membrane using
ImageJ software (version 1.42q). Images of 10 NMJs
from each mouse were obtained for quantification.
Preparation of IgG Fractions and Fab
Fragments from MuSK Antisera
Sera from MG-affected mice were collected, and the
IgG fraction was purified with Protein G-Sepharose (GE
Healthcare) as anti-MuSK IgG. Fab fragments of anti-
MuSK IgG were prepared using a Pierce mouse IgG1
Fab preparation kit (Thermo Scientific, Rockford, IL)
with papain digestion. As a control, IgG fractions (nor-
mal IgG) and Fab fragments (normal Fab) were pre-
pared from sera of preimmune mice using the same
method.
AChR Clustering Assay
The C2C12 cell line was obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and used
for three to eight passages. Cells were cultured in 12-well
plates as myoblasts in 10% fetal calf serum (FCS)/Dul-
becco’s modified Eagle’s medium. When the cells
reached confluency, myotube formation was induced byreplacing the medium with 2% horse serum/Dulbecco’s
modified Eagle’s medium. The cells were incubated for 3
days, with fresh medium exchange every day, until full
differentiation into multinucleated myotubes was ob-
served morphologically. Preparation of recombinant
agrin protein was as described previously.7 Myotubes
were treated with 10 g/mL anti-MuSK IgG or Fab for 30
minutes, and then incubated for 16 hours with 1 nmol/L
agrin. AChR clustering was visualized after incubation
with 40 nmol/L Alexa Fluor 594-BTx (Invitrogen) in fusion
medium for 1 hour at 37°C before fixation. Fluorescence
images of myotubes were acquired using a 20 objec-
tive on a Leica DMI6000 microscope; the number of
AChR clusters in six randomly selected fields was
counted.
MuSK Phosphorylation Assay
The C2C12 myotubes were treated with either 10 g/mL
anti-MuSK IgG or Fab. After 30 minutes, half of the myo-
tube cultures were further treated for 30 minutes with 1
nmol/L agrin, and the remaining cultures were left un-
treated. The myotubes were lysed and solubilized using a
protease inhibitor cocktail (complete EDTA-free; Roche
Applied Science, Indianapolis, IN) with 2 mmol/L sodium
orthovanadate. Extracts were immunoprecipitated with
antibodies directed against MuSK, and the resulting pre-
cipitates were immunoblotted with either a mixture of the
anti-phosphotyrosine antibodies 4G10 (Millipore, Bil-
lerica, MA) and PY20 (Millipore-Chemicon International)
or MuSK antibodies. Antibodies directed against MuSK
were generated in rabbits as described previously.7
Band intensities of immunoblots were assessed using
ImageJ software (version 1.42q).
Statistical Analysis
Significant differences between control and MuSK-in-
jected mice were analyzed by unpaired t-test. Paired
t-test was used to analyze the effect of neostigmine treat-
ment in EMG experiments. Analysis of variance was used
to assess AChR clustering and MuSK phosphorylation
assays. P values of 0.05 were considered statistically
significant.
Results
MuSK Protein Injection Results in Synchronous
Muscle Weakness with Weight Loss
A/WySnJ mice were injected with 20 g of MuSK protein
on days 0 and 14 of the experiment. Because A/WySnJ
mice carry mutations that result in C5 deficiency,19 these
mice cannot generate a lytic membrane attack complex
and are therefore highly resistant to EAMG after AChR
immunization.20,21 All mice (n  18) injected with MuSK
manifested severe muscle weakness with tremors within
2 weeks of the second injection. These symptoms oc-
curred synchronously in all animals, along with the ap-
pearance of a prominent cervicothoracic hump, indicat-
MuSK A
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addition, MuSK-injected mice exhibited significant weight
loss and muscle weakness (Figure 1, B and C). By con-
trast, neither vehicle-injected mice (n 5; Figure 1, B and
C) nor OVA-injected mice (n  5; data not shown) exhib-
ited weight loss or muscle weakness. We also injected
three A/WySnJ mice with Torpedo californica AChR pro-
tein three times (at days 0, 14, and 42) and found no
effect on body weight or muscle strength in these mice
(data not shown).
IgG1 Is a Predominant Subclass in MuSK Abs
To test whether muscle weakness of the mice corre-
lates with serum titers of MuSK protein, we used ELISA.
Anti-MuSK IgG antibodies were detectable in all MuSK-
injected mice, whereas control mice (n  5) had no
detectable antibodies to MuSK, which was similar to
the preimmune sera (Figure 1D). Isotyping analysis
A
C D
B
Figure 1. Manifestation of MG-like phenotypes after MuSK injection of A/
cervical hump and were unable to raise their heads. Control mice injected w
muscle strength (C) after the second injection, compared with control mice.
first injection. n  5, control; n  18, MuSK-injected. Data are reported as m
in MuSK immunoreactivities of sera after MuSK immunization. Sera from MG
assay. Values of absorbance at 450 nm were determined as MuSK immunorea
MuSK Abs were predominantly of the IgG1 subclass, with small amounts of Ig
for assay. Values of absorbance at 405 nm were determined as amounts of
symbols, control; filled symbols, MuSK.revealed that MuSK Abs were predominantly of theIgG1 subclass, along with smaller amounts of IgG2a
and IgG2b (Figure 1E). No other subclasses tested
were detected in the MuSK Abs. Mouse IgG1 has func-
tional similarities with human IgG4 in terms of electro-
phoretic mobility and T-helper type 2 dependency for
production.22 Thus, MuSK-MG in patients and in
A/WySnJ mice seems to share a common immune reg-
ulatory pathway.
MuSK Abs Change Both Presynaptic and
Postsynaptic Structures
To assess directly whether the presence of MuSK Abs
results in NMJ structural changes, whole mounts of so-
leus muscles from MuSK-injected and control mice were
double-labeled with BTx (a probe for AChRs), as well as
a cocktail of antibodies against neurofilaments and the
synaptic vesicle marker synaptophysin (markers for
motor neuron axons and terminals, respectively). Ex-
E
ice. A: A/WySnJ mice injected with MuSK protein exhibited a prominent
icle showed no such malformation. MuSK-injected mice lost weight (B) and
nt weight reduction was observed in MuSK-injected mice at day 26 after the
SEM. *P  0.05; **P  0.01 versus control A/WySnJ mice (t-test). D: Change
d mice contained a high titer of MuSK Abs. Sera were prediluted 1:1000 for
*P  0.01 versus preimmune sera (t-test). E: Isotyping analysis of MuSK Abs.
IgG2b, but no detectable IgG3, IgM, IgA, or IgE. Sera were prediluted 1:3000
b subclasses. **P  0.01 versus IgG1 subclass (analysis of variance). OpenWySnJ m
ith veh
Significa
eans 
-affecte
ctivity. *
G2a andtended-focus images collected by confocal microscopy
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ysis. Accordingly, areas of AChR-clustering and of ap-
posing nerve terminals of NMJs were significantly
smaller in soleus muscles of MuSK-injected mice (n 
109 NMJs from three mice), compared with controls
(n  126 NMJs from three mice) (Figure 2, A–C). Fur-
thermore, the density of AChR clustering at NMJ post-
synaptic membranes was reduced in soleus and other
muscles of MuSK-injected mice, compared with control
mice, as evidenced by the intensity of BTx at NMJs
(Figure 2, A and B). In addition, axon sprouting, with or
without the remnants of nerve terminals, was prominent
at the NMJs of MuSK-injected mice (Figure 2A). These
results are consistent with the axon outgrowth and
reduced AChR clustering observed in other animal
models of MuSK-MG.8,23,24 These results also indicate
that MuSK is required by mature NMJs for maintenance
of AChR clustering at the postsynaptic membrane and
apposing motor terminals. Because MuSK is ex-
pressed in skeletal muscle but not in motor neurons,25
MuSK likely acts via retrograde signals to affect pre-
A
B C
Figure 2. Disorganization of both presynaptic and postsynaptic structures in
MuSK-injected mice. A: Whole-mount staining of NMJs from soleus muscles.
Axons and nerve terminals (green) were stained with anti-neurofilament and
anti-synaptophysin antibodies (NF  Syn), and AChRs (red) were labeled
with rhodamine-BTx. Some NMJs with axon sprouts were observed in MuSK-
injected mice (arrowheads). Scale bars: 30 m. B: Soleus muscle nerve
terminals were stained with anti-synaptophysin (green) and AChRs were
stained with rhodamine-BTx (red). C: Synaptophysin and rhodamine-BTx-
stained areas decreased to 54.8% and 45.6% of control levels, respectively, in
MuSK-injected mice. Scale bars: 20 m. Data are expressed as means  SEM
from30 NMJs of each mouse (n 3 mice/group). **P 0.01 versus control
(t-test).synaptic NMJ structures.Changes in Three-Dimensional Structures of the
NMJ Subneural Apparatus
Using SEM, we studied the three-dimensional organiza-
tion of the subneural apparatus at NMJs in tibialis anterior
muscles after removing presynaptic terminals and con-
nective tissues.18 In control mice, the subneural appara-
tus consisted of complex labyrinthine postsynaptic gut-
ters, approximately 0.9 to 2.8 m in width, containing
numerous slit-like junctional folds. In MuSK-injected
mice, however, the subneural apparatus had shallow gut-
ters and lost both labyrinthine structures and formerly
prominent slit-like junctional folds (Figure 3A). TEM ob-
servations made in diaphragm muscles revealed that
synaptic folds underneath motor terminals underwent a
pronounced loss in MuSK-injected NMJs, compared
with control mice (Figure 3, B and C). Of note, the
synaptic membrane was well preserved in MuSK-in-
jected animals (Figure 3B), and we observed no com-
plement-mediated destruction of synaptic structures.26
These data indicate that MuSK is required for the main-
tenance of the subneural apparatus and that the re-
duction of synaptic folds in MuSK-injected mice likely
impaired synaptic transmission and caused muscle
weakness in these animals.
Figure 3. Disruption of NMJ ultrastructure in MuSK-injected mice. A: Com-
plex synaptic gutters containing numerous slit-like junctional folds were
observed by SEM in NMJs of control tibialis anterior muscle. Synaptic gutter
flattening and a decreased number of slit-like junctional folds were observed
in NMJs of MuSK-injected mice. Scale bars: 15 m. B: Evenly distributed
junctional folds (arrowhead) of comparable depth were observed in con-
trols via TEM. Loss of junctional folds was observed in MuSK-injected mice.
Scale bars: 500 nm. C: Junctional fold densities were significantly decreased
in MuSK-injected mice. Data are expressed as means  SEM from 10 NMJs
of each mouse (n  3 mice/group). **P  0.01 versus controls (t-test).
804 Mori et al
AJP February 2012, Vol. 180, No. 2Both Divalent and Monovalent MuSK IgG
Perturb MuSK Signaling in C2C12 Myotubes
Because our histological studies demonstrated that
MuSK Abs caused EAMG without complement activation,
we next tested MuSK Abs in sera from MuSK-injected
mice for the ability to interfere with MuSK function in vitro.
Agrin has been shown to induce the clustering of AChRs in
C2C12 myotubes after autophosphorylation by MuSK.27
When agrin and purified IgG antibodies from the sera of
MuSK-injected mice were added to C2C12 myotubes,
there was a significant reduction in the marked AChR
clustering observed in the presence of purified IgG anti-
bodies from normal sera (Figure 4, A and B). Because
inhibition of MuSK signaling by MuSK Abs might have
inhibited AChR clustering on C2C12 cells, we analyzed
the effect of these antibodies on MuSK phosphorylation.
However, MuSK-IgG antibodies induced tyrosine phos-
phorylation of MuSK in the absence of agrin, and these
antibodies did not inhibit activation by agrin (Figure 4, C
and D), as described previously,7,28 suggesting that the
divalent MuSK Abs altered a downstream pathway in-
stead of inhibiting MuSK signaling directly.
Next, we generated monovalent Fab fragments of
MuSK-IgG antibodies by papain digestion to determine
whether they were sufficient to block MuSK signaling in
C2C12 cells. Although monovalent Fab fragments of
MuSK-IgG antibodies did not activate autophosphoryla-
tion of MuSK in the absence of agrin (Figure 4, C and D),
these Fab fragments significantly inhibited agrin-induced
AChR clustering and MuSK phosphorylation (Figure 4,
A–C). These results indicate that monovalent MuSK Abs
can block MuSK function in vitro.
Neuromuscular Transmission Is Impaired in
MuSK-Injected Mice
We performed electrophysiology experiments to deter-
mine the effect of MuSK Abs on neuromuscular transmis-
sion in mature NMJs. First, we performed EMG experi-
ments in the gastrocnemius muscles of MuSK-injected
Figure 4. Inhibition of agrin-induced MuSK function in cultured myotubes
by anti-MuSK IgG and Fab fragments. A: C2C12 myotubes were treated with
either normal IgG/Fab (10 g/mL) or anti-MuSK IgG/Fab (10 g/mL) for 30
minutes and then were incubated with 1 nmol/L agrin for 16 hours. AChR
clusters were labeled with Alexa Fluor 594-BTx. Scale bar  100 m. B: The
number of AChR clusters decreased significantly in anti-MuSK IgG or Fab-
treated myotubes. Quantification was performed on six randomly selected
fields from each of four experiments, and data are expressed as means 
SEM. **P  0.01 versus no treatment; ††P  0.01 versus treatment with agrin
 normal IgG; ‡‡P 0.01 versus treatment with agrin normal Fab (analysis
of variance). C: C2C12 myotubes were treated with either normal IgG/Fab or
anti-MuSK IgG/Fab for 30 minutes. Half of the myotube cultures were then
treated with 1 nmol/L agrin (Ag) for 30 minutes. Cell extracts were immu-
noprecipitated with MuSK antibody and immunoblotted with anti-phospho-
tyrosine (PY-blot) and anti-MuSK. D: Divalent anti-MuSK IgG treatment
induced MuSK phosphorylation in the absence of agrin, but treatment with
monovalent anti-MuSK Fab significantly inhibited agrin-induced MuSK phos-
phorylation. Band intensities of the PY-blot were normalized to total MuSK.
Data are expressed as means  SEM from three experiments. **P  0.01
versus treatment with normal IgG; †P  0.05 versus treatment with normal
‡Fab; P  0.05 versus treatment with agrin  normal Fab (analysis of
variance). Control: open symbols; MuSK: filled symbols.
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tion at 3 Hz elicited a declining CMAP response reminis-
cent of that observed in MG patients, whereas the
CMAPs of control mice exhibited no such decline in re-
sponse (Figure 5A). CMAP amplitude declined by an
average of 25.8  3.2% (n  10) in MuSK-injected mice
(Figure 5B). These results indicate that a failure of neu-romuscular transmission was the likely cause of muscle
weakness in MuSK-injected mice.
Next, we analyzed the MEPPs and EPPs of MuSK-
injected mice via intracellular recordings from muscle
fibers of excised hemi-diaphragms.17,29 No significant
difference was observed in resting membrane potential
between control mice (64.1  0.96 mV) and MuSK-
injected mice (65.4 1.33 mV). In MuSK-injected mice,
both MEPP and EPP amplitudes (MEPP, 0.45  0.03 mV;
EPP, 10.2  0.67 mV; n  47 NMJs in 4 mice) were
significantly decreased, compared with controls (MEPP,
0.98  0.06 mV; EPP, 22.4  0.92 mV; n  63 NMJs in 3
mice) (Figure 5, C–F). A decrease in EPP amplitude could
result either from fewer transmitter quanta being released
by a single nerve impulse or from a smaller effect of
individual quanta.30 In addition to the decreased MEPP
amplitude, which indicates a smaller postsynaptic effect,
the mean quantal content (ie, the steady-state number of
quanta released by a single nerve impulse under stimu-
lation at 0.7 Hz) of MuSK-injected diaphragms was also
decreased, falling to 33.3  1.78 (or 66.2% of the normal
value, 50.3  2.92) (Figure 5G). Taken together, these
two effects could result in decreased EPP amplitude,
leading to CMAP amplitude decrements.
In addition to the decrease in stimulation-dependent
quantal release, MuSK-injected mice (0.35  0.04/s; n 
48 NMJs in 4 mice) exhibited a 52% reduction in spon-
taneous release, as observed in MEPP frequency, com-
pared with controls (0.67  0.02/s; n  61 NMJs in 4
mice) (Figure 5, H and I). Because MuSK protein injection
resulted in decrease in MEPP amplitude due to the loss of
AChR clusters, we could not exclude the possibility that
some of the emerging MEPPs were undetectable by our
method. However, these results might indicate a low
probability of spontaneous quantal ACh release resulting
from a presynaptic defect in MuSK-injected mice, as
described previously.31,32
MuSK-EAMG Is Inducible in Other
Complement-Deficient Strains of Mice
A/WySnJ mice exhibit a significant loss of mature B cells
due to the B-cell maturation defect-1 (Bcmd-1) mutant
allele of B-cell-activating factor receptor (BAFF-R), and
are genetically prone to develop B cell-mediated autoim-
munity.33,34 [ BAFF-R has since been reclassified as tu-
mor necrosis factor receptor superfamily, member 13c
Figure 5. Impairment of neuromuscular transmission after MuSK injection.
A: Representative EMG traces during repetitive nerve stimulation. MuSK-
injected mice exhibited a decremental CMAP amplitude response, consistent
with MG. B: MuSK-injected mice exhibited significant CMAP decline (mean,
25.8  3.2%). n  3, control; n  10, MuSK-injected. Representative MEPP
(C) and EPP (D) traces from diaphragm muscles. Mean amplitudes of both
MEPPs (E) and EPPs (F), as well as mean quantal release by nerve stimulation
(G), were decreased in MuSK-injected mice to 45.9%, 45.5%, and 66.2% of
control values, respectively. Data are expressed as means  SEM from 10
NMJs of each mouse (n  3, control; n  4, MuSK-injected). H: Represen-
tative MEPP recordings from diaphragm muscles. I: MEPP frequencies were
decreased to 52.0% of control levels in MuSK-injected mice. Data are ex-
pressed as means SEM from10 NMJs of each mouse (n 4 mice/group).
**P  0.01 versus controls (t-test).
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mutant allele affects the onset of MuSK-EAMG regardless
of C5 deficiency, several strains of mice carrying no
Bcmd-1 mutant allele (A/J, DBA/2, FVB/N), but exhibiting
the same C5 deficiency as A/WySnJ,19 were injected with
MuSK protein in the same manner and on the same
schedule. Almost all of the mice tested exhibited a
marked decrease in body weight in addition to impair-
ment of neuromuscular transmission, indicating that a
severe form of MuSK-EAMG is inducible in other C5-
deficient strains at high incidence (Table 1). Of note,
these mice were more sensitive to the onset of MuSK-
EAMG than were complement-sufficient mice, such as
B10.A-H2a, BALB/c, and C57BL/6. Notably, approxi-
mately one half of the C57BL/6 mice examined exhibited
neither significant weight loss nor neuromuscular trans-
mission defect, despite receiving three injections (Table
1). These results imply that C5-deficient strains may
share the genetic background that confers susceptibility
to severe MuSK-EAMG.
To validate the results obtained using A/WySnJ mice,
genetically engineered C3-deficient mice were used to
induce MuSK-EAMG.35 Although two out of five MuSK-
injected mice exhibited moderate (20%) weight reduc-
tion 2 weeks after the third injection (see Supplemental
Figure S1 at http://ajp.amjpathol.org), these mice exhib-
ited a significant decrease in muscle strength, compared
with controls. In addition, all MuSK-injected mice exhib-
ited a decremental CMAP amplitude response after re-
petitive nerve stimulation, indicating that neuromuscular
transmission was impaired (see Supplemental Figure S1,
D and E, at http://ajp.amjpathol.org). In whole-mount
staining of soleus muscles from MuSK-injected mice, the
pretzel-like structures of AChR clusters were totally dis-
assembled, and axon sprouting was observed in many
NMJs (see Supplemental Figure S1F at http://ajp.
amjpathol.org). Taken together, these results are consis-
tent with those obtained from A/WySnJ mice, confirming
that complement activation is dispensable for the onset of
MuSK-EAMG.
MuSK Abs Impair AChE Function at NMJs
AChE inhibitors are an effective for treatment of AChR-MG
symptoms, but may cause muscle cramps, fasciculation,
Table 1. Incidence of MuSK-MG in Seven Mouse Strains
Strain
Total number
of mice
M
No symptoms
A/WySnJ 18 0
A/J 5 0
DBA/2 5 0
FVB/N 5 0
B10.A-H2a 4 0
BALB/c 4 1
C57BL/6 11 6
CMAP, compound muscle action potential.dysphagia, and respiratory insufficiency in MuSK-MG pa-tients.14,36 Therefore, to investigate the effect of AChE-inhi-
bition on recovery of neuromuscular transmission, we
administered the AChE inhibitor neostigmine to MuSK-
injected mice, and recorded CMAPs by repetitive nerve
stimulation before and 20 minutes after neostigmine ad-
ministration (37.5 g/kg). Although all neostigmine-
treated, MuSK-injected mice (n  6) exhibited a signifi-
cant reversal in CMAP decline, only one mouse
recovered CMAP to within 10% of the decline (9.2%),
which is considered a normal response (Figure 6, A and
B). Of note, in two neostigmine-treated, MuSK-injected
mice, we recorded an abnormal EMG pattern 5 to 20 ms
after the CMAP peak in the first trace in a stimulation
series, as is observed in MuSK-MG patients after AChE
inhibitor treatment (Figure 6C).37,38 Furthermore, another
abnormal EMG pattern related to a congenital myas-
thenic syndrome caused by an AChE deficiency was
recorded in a separate MuSK-injected mouse (Figure
6D).39 Repetitive nerve stimulation at 3 Hz elicited a sec-
ond CMAP with smaller amplitude than the first, a mod-
erate decline of the primary CMAP, and a faster decline
of the secondary CMAP. We did not observe abnormal
EMG patterns after neostigmine injection in control mice
(data not shown). These observations indicate abnor-
mal sensitivities to ACh at endplates after MuSK injec-
tion, and suggest that the pathological conditions of
patients with neuromuscular disorders could be repro-
duced in MuSK-injected mice.
Given that abnormal electrophysiological signs have
been observed in MuSK-MG patients administered an
overdose of AChE inhibitors or in patients with congenital
myasthenia with AChE deficiency,38,39 we postulated that
AChE deficiency relative to ACh activity at NMJs might be
the cause of these abnormalities. We therefore examined
the expression of AChE and the AChE-anchoring protein
ColQ, which may bind to MuSK and promote the accu-
mulation of AChE at the postsynaptic membrane.40,41
Using BTx and antibodies against AChE and ColQ, we
triple-labeled soleus muscle whole mounts from MuSK-
injected and control mice. The intensities of both AChE
and ColQ expression at NMJs in MuSK-injected mice
were reduced (Figure 6E), and the area of AChE expres-
sion was decreased significantly in MuSK-injected mice
(n  104 NMJs in 3 mice), compared with control mice
ptoms (no. of mice)
Incidence (%)
10% CMAP decrement
weight loss 20% weight loss
0 18 100
0 5 100
1 4 100
0 5 100
4 0 100
1 2 75.0
4 1 45.5G sym
20%(n  91 NMJs in 3 mice) (Figure 6, E and F).
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function by examining the rate of EPP decay, the EPP
decay time constant (), using intracellular recordings as
described above.42 In traces with similar amplitudes, the
falling phase of the EPP of MuSK-injected mice was not
as steep as that of controls (Figure 6G), and the mean
EPP  of MuSK-injected mice (4.85  0.16 ms, n  30
A
C D
E F
G H
B
Figure 6. Impairment of AChE function in MuSK-injected mice. A: Repre-
sentative EMG traces before and after neostigmine treatment. B: Neostigmine
induced a significant reversal of CMAP decrement, ranging from 23.4% to
54.1% (mean, 36.4  4.8%). **P  0.01 (paired t-test). C and D: Abnormal
EMG traces evoked by neostigmine treatment. After neostigmine treatment,
disturbance of baseline (arrows) after CMAP emerged in the first trace only
(C), and a second CMAP (arrow) emerged, with smaller amplitude than the
first, and then gradually disappeared (D). E: Levels of antibody staining for
AChE (green), ColQ (cyan), and Alexa Fluor 647-BTx labeling of AChRs (red)
were reduced in soleus muscles of MuSK-injected mice, compared with
controls. Scale bars: 10 m. F: The average AChE staining area decreased to
65.8% of control values in MuSK-injected mice; 30 NMJs from each mouse
(n  3 mice/group) were quantified. G: Representative EPP traces from
control and MuSK-injected mouse diaphragms. In EPP traces with equivalent
amplitudes, MuSK-injected mice exhibited longer EPP decay time constants
(  5.0 ms), compared with controls (  2.6 ms). H: The mean EPP  of
MuSK-injected mice was 164% that of control mice. Data are expressed as
means SEM from10 NMJs of each mouse (n 3 mice/group). **P 0.01
versus control mice (t-test).NMJs in 3 mice) was longer than that of controls (2.95 0.07 ms, n  53 NMJs in 3 mice) (Figure 6H), indicating
that the AChE at NMJs in MuSK-injected mice could not
hydrolyze ACh rapidly, leading to prolonged ACh action.
Taken together, our results demonstrate that MuSK is
required for the binding of AChE clusters to ColQ at the
NMJ postsynaptic membrane in vivo and that MuSK Abs
interfered with AChE function, leading to hypersensitivity
to ACh after neostigmine treatment.
Discussion
In the present study, we investigated the pathophysiol-
ogy of MuSK-MG using a new animal model in which
100% of mice synchronously develop MG after MuSK
protein injection. In addition, we demonstrated the patho-
genicity of MuSK Abs and found novel roles for MuSK
activity at mature NMJs.
We previously demonstrated the pathogenicity of
MuSK Abs via active immunization of rabbits with recom-
binant soluble MuSK protein.7 In addition, EAMG induced
by inoculation of MuSK protein has also been success-
fully established in mice.23,43 Furthermore, when passive
transfer of human MuSK Abs from MG patients into mice
caused severe muscle weakness,8 and EMG results were
compatible with a diagnosis of MG, the pathogenicity of
MuSK Abs was confirmed. Although it has been postu-
lated that the human IgG4 subclass of autoantibodies
causes MuSK-MG without complement activation, previ-
ous pathophysiological studies did not include comple-
ment-deficient animals.9,10,44
The A/WySnJ mouse strain cannot generate the mem-
brane attack complex, which is the cytolytic end product
of the complement cascade, because of mutations in the
complement component 5 gene (C5).19 Thus, the use of
this strain allowed us to completely eliminate the role of
complement activation on the onset of MG and to analyze
non-complement-mediated effects. Previously, a high in-
cidence of EAMG after MuSK immunization was also
observed in A/J mice, which exhibit the same C5 defi-
ciency as A/WySnJ mice.23 We demonstrated that not
only A/J but also other C5-deficient strains exhibited a
severe form of MuSK-EAMG at a high incidence, as ob-
served in the A/WySnJ strain. Complement-mediated
damage to postsynaptic membranes is considered to be
the major pathogenic mechanism in AChR-MG, because
complement-deficient mice are resistant to EAMG in-
duced by AChR immunization.20,21 However, our results
demonstrate that complement activation is not necessary
for the onset of MuSK-MG, and provide insight into the
mechanism by which the IgG4 subclass of MuSK Abs
causes human MG.9,10
The IgG4 subclass of MuSK Abs observed in MG pa-
tients may have a functionally monovalent antigen-bind-
ing site, because IgG4 exchanges Fab arms with non-
pathogenic IgG4 in vivo.45 Therefore, this particular IgG4
may not efficiently reduce the number of MuSK molecules
on the surface of postsynaptic membranes by invoking a
cross-linking mechanism requiring divalent antibodies.
Although no dynamic exchange of the IgG-Fab arm is
found in mouse IgG subclasses, we demonstrated in
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inhibited MuSK signaling and AChR clustering. There-
fore, MuSK antibody binding could directly inhibit
MuSK function required for the maintenance of mature
NMJs, as well as internalization of MuSK molecules
from the plasma membrane.7,46
In the present study, we demonstrated that MuSK is
required for maintenance of mature NMJ structure and
function. Our complement-deficient mouse model exhib-
ited a loss of AChR expression, as well as a reduction in
the size of motor terminals apposing AChR clusters at
NMJs. These changes were consistent with those observed
in complement-sufficient animals that developed MuSK-
EAMG7,8,23,43 and in mice bearing the MuSK mutations
observed in congenital myasthenic syndrome.47,48 Further-
more, our ultrastructural studies indicate a significant loss
of complexity in convoluted postsynaptic structures (eg,
the flattening of synaptic gutters), as well as a decrease
in the number of slit-like junctional folds at postsynaptic
membranes.
In addition to morphological defects, our model exhib-
ited functional defects at presynapses, including lower
levels of transmitter release from nerve terminals. In clin-
ical studies, low levels of presynaptic ACh release were
found at NMJs of a MuSK-MG patient using in vitro elec-
trophysiology, which is consistent with our results.49,50 It
has been shown that AChR-MG, which is caused exclu-
sively by postsynaptic defects, results in an increase in
quantal content in both patients and EAMG model ani-
mals, suggesting the involvement of a compensatory ret-
rograde signaling mechanism between postsynaptic and
presynaptic sites.51,52 Therefore, the decrease in quantal
content in MuSK-MG might imply dysfunction of this com-
pensatory mechanism, suggesting that MuSK mediates
retrograde signaling involving transmitter release from
nerve terminals. In this regard, mice that carry an inacti-
vated form of the gene encoding muscle-specific
-catenin, a signaling protein downstream of disheveled
(Dvl), or laminin 2, also have morphological defects
both presynaptically and postsynaptically.31,32 These
data point to the important roles these molecules play in
NMJ formation. Furthermore, both spontaneous and
evoked ACh release from nerve terminals are reduced by
abnormalities in the vesicle release machinery or reduc-
tions in the number of release sites. Therefore, we cannot
exclude the possibility that the defects observed in our
EAMG model might result from impairment of the presyn-
aptic component itself, via dysfunction of MuSK (although
it is generally assumed that the reductions observed in
presynaptic and postsynaptic areas are related to dimin-
ished ACh release17). Our data suggest that MuSK plays
a role in the maintenance of presynaptic function at NMJs
through retrograde signaling.
We demonstrated that MuSK is required for proper AChE
function at NMJs and determined the mechanism by which
AChE inhibitor treatment exacerbates MuSK-MG symp-
toms. It is clear that MuSK participates in the accumulation
of AChE in the synaptic basal lamina of NMJs, possibly by
forming complexes with ColQ, as postulated previously
based on in vitro experiments.41 MuSK might act as a
scaffold molecule, anchoring those complexes to thesynaptic basal lamina. Additionally, MuSK signaling may
be required for the highly localized expression of AChE
mRNA at mature NMJs.53,54 Accumulated AChE in the
synaptic cleft may tightly limit both the temporal and
spatial extent of cholinergic neurotransmission by rapid
cleavage of ACh at the basal lamina. However, inhibition
of MuSK by MuSK Abs decreased levels of AChE at the
basal lamina and impaired its function, as shown by the
prolonged EPP time constant we observed. If AChE in-
hibitors were to be administered in these conditions, the
rebinding to AChRs by an excess of ACh existing at the
synaptic cleft could provoke cholinergic hypersensitivity
(recorded as an abnormal EMG pattern) and so could
eventually lead to cholinergic crises.
Clinically, MuSK-MG patients tend to have severely
weak, atrophied muscles and are more refractory to treat-
ment than AChR-MG patients. These differences in clin-
ical symptoms between MuSK-MG and AChR-MG could
result from the distinct pathogenic mechanisms involved
in these two types of MG. Overall, our results indicate that
MuSK plays indispensable roles in the structural and
functional maintenance of mature NMJs, and that disrup-
tion of MuSK function by specific autoantibodies causes
MG (Figure 7). One of the main signals that cause ad-
vancement from presynapse to postsynapse stages is
the agrin/MuSK pathway, but the retrograde signals reg-
ulated by MuSK are still elusive. Although fibroblast
growth factors, laminin 2, and collagen (IV) chains act
as muscle-derived organizers of presynaptic differentia-
tion, whether they act in conjunction with MuSK signaling
is uncertain.55,56 Our model of MuSK-MG did not exhibit
immune complex-mediated damage to tissue that would
otherwise participate in this interaction. Our model thus
provides a valuable platform from which to evaluate the
role of MuSK signaling in NMJ maintenance and the
immune mechanisms and pathophysiology of MuSK-MG.
A B
Figure 7. Pathogenic mechanism of MG induced by MuSK Abs. A: In normal
NMJs, agrin binds to LRP4 to activate MuSK. MuSK regulates the maintenance
of both presynaptic and postsynaptic structures and functions bidirectionally.
B: MuSK Abs bind to the ectodomain of MuSK, causing MuSK degradation by
antigenic modulation and/or direct inhibition of MuSK function. This inhibits
MuSK, resulting in structural disruptions (eg, dispersal of AChR clusters, loss
of synaptic folds, and degeneration of nerve terminals) and functional ab-
normalities (eg, decrease in ACh release) that eventually lead to MG. Fur-
thermore, the decreased levels of AChE, which is anchored to MuSK by ColQ,
can induce a cholinergic crisis mediated by AChE inhibitors, exacerbating the
symptoms of MG.
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velopment of effective medications for this group of dev-
astating diseases.
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